Bristol Myers Squibb Rises 5% as Cancer Pipeline Wins Draw Investors Amid Patent Cliff Concerns

Bristol Myers Squibb shares climbed 5% on Tuesday, October 20, outperforming most competitors on a strong day for the broader healthcare sector, which hit record highs. The rally came as investors weighed a string of recent oncology advances against the revenue pressure from approaching patent expirations on older drugs.

The company's radiopharmaceutical candidate RYZ101 met its primary endpoint for progression-free survival in the Phase III ACTION-1 trial on October 12, covering certain advanced gastrointestinal and pancreatic neuroendocrine tumors. That result, combined with additional progress in multiple myeloma, widened the potential revenue base of the pipeline, though analysts cautioned that launch timing and the cost of building a specialized radiopharmaceutical supply chain mean clinical wins do not translate immediately into quantified revenue.

Bristol Myers lifted its full-year 2026 guidance to roughly 49 billion to 50 billion dollars in revenue and 6.75 to 7.00 dollars in non-GAAP earnings per share, supported by stronger new-drug sales. The core question for investors remains whether the growth portfolio can scale fast enough to replace billions in sales that will face generic and patent pressure from older franchises.

Unusual options activity in BMY was flagged Tuesday, with notable put volume in the October 30 expiry at the 57 dollar strike, suggesting some traders were hedging near-term downside even as the stock rose. The sector tailwind on the day was partly driven by Moderna's 7% surge ahead of a Phase 3 melanoma vaccine data presentation at the ESMO Congress 2026, with Eli Lilly also touching a new all-time high.